Related Experiment Videos
Imatinib mesylate causes hypopigmentation in the skin
Anne S Tsao1, Hagop Kantarjian, Jorge Cortes
1Medical Oncology Fellowship Program, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer
|November 25, 2003
Summary
Skin hypopigmentation is a reversible side effect of imatinib mesylate treatment in CML patients. This benign finding did not predict treatment response, suggesting a manageable toxicity profile for this tyrosine kinase inhibitor.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Imatinib mesylate is a tyrosine kinase inhibitor targeting BCR-ABL, KIT, and PDGF receptors, crucial in treating Chronic Myeloid Leukemia (CML).
- Common imatinib side effects include nausea, diarrhea, edema, and myelosuppression, but skin hypopigmentation is less documented.
Observation:
- This case series details skin hypopigmentation in six CML patients treated with imatinib mesylate.
- Hypopigmentation onset occurred within the first month of therapy, often alongside other drug toxicities.
Findings:
- Skin hypopigmentation was a benign and reversible side effect, potentially dose-related.
- The presence of hypopigmentation did not correlate with leukemic cell response or clinical outcomes.
- All patients achieved hematologic response, with two showing complete cytogenetic response despite hypopigmentation.
Implications:
- Imatinib-induced hypopigmentation is manageable through dose reduction or discontinuation.
- The mechanism involves KIT signaling pathways regulating melanocyte development, offering insights into imatinib's dermatologic effects.
- Understanding this side effect aids in managing patient care and optimizing imatinib therapy in CML treatment.